Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics  

作　　者：Jie-Li Hu Ai-Long Huang 

机构地区：[1]Key Laboratory of Molecular Biology on Infectious Diseases,Ministry of Education,Chongqing Medical University,Chongqing,400016,China

出　　处：《Virologica Sinica》2024年第1期9-23,共15页中国病毒学（英文版）

基　　金：supported by grants from the National Key R&D Program of China(2022YFA1303600);the Natural Science Foundation of Chongqing(cstc2021jcyj-msxmX0298);the Science and Technology Research Program of Chongqing Municipal Education Commission(Grant No.KJZD-K202200409);the 111 Project(No.D20028),Key Laboratory of Molecular Biology on Infectious Diseases,Ministry of Education,Chongqing Medical University(No.202104);CQMU Program for Youth Innovation in Future Medicine(No.W0049).

摘　　要：The achievement of a functional cure for chronic hepatitis B(CHB)remains limited to a minority of patients treated with currently approved drugs.The primary objective in developing new anti-HBV drugs is to enhance the functional cure rates for CHB.A critical prerequisite for the functional cure of CHB is a substantial reduction,or even eradication of covalently closed circular DNA(cccDNA).Within this context,the changes in cccDNA levels during treatment become as a pivotal concern.We have previously analyzed the factors influencing cccDNA dynamics and introduced a preliminary classification of hepatitis B treatment strategies based on these dynamics.In this review,we employ a systems thinking perspective to elucidate the fundamental aspects of the HBV replication cycle and to rationalize the classification of treatment strategies according to their impact on the dynamic equilibrium of cccDNA.Building upon this foundation,we categorize current anti-HBV strategies into two distinct groups and advocate for their combined use to significantly reduce cccDNA levels within a well-defined timeframe.

关 键 词：Hepatitis B CCCDNA Functional cure DYNAMICS Treatment Strategy 

分 类 号：R373.21[医药卫生—病原生物学]